Abstract: A shipping crate is provided having multiple walls. In each wall, a first wall layer has sides and a first thickness and a second wall layer has sides extending past each of the sides of the first wall by the first thickness. The crate also has a back panel having a first back panel layer and at least a partial second back panel layer. The first back panel layer has sides and a thickness substantially similar to the first thickness and the second back panel layer extends past each of the sides of the first back panel layer by the first thickness. When assembled, the first wall layers of each of the walls combine to form a post and lintel assembly. The second wall layers of each of the plurality of walls combine to form a second post and lintel assembly distinct from the first post and lintel assembly.

Abstract: The present invention provides systems and methods employing a conferencing system for facilitating enhanced communication between users. In certain embodiments, the conferencing system comprises a communication interface configured to, during a conference session, provide a virtual and/or augmented conference between multiple users having access to a multi-channel, multi-access, always-on, and non-blocking communication. In particular embodiments, the communication interface is in communication with at least one additional component select from: a video component, a data component (e.g., that provides non-audio data to one or more of said users), an audio/video ambience component, and a whiteboard component.

Abstract: The present invention is related to new derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to dihydroisoquinoline derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

Abstract: A shipping crate is provided having multiple walls. In each wall, a first wall layer has sides and a first thickness and a second wall layer has sides extending past each of the sides of the first wall by the first thickness. The crate also has a back panel having a first back panel layer and at least a partial second back panel layer. The first back panel layer has sides and a thickness substantially similar to the first thickness and the second back panel layer extends past each of the sides of the first back panel layer by the first thickness. When assembled, the first wall layers of each of the walls combine to form a post and lintel assembly. The second wall layers of each of the plurality of walls combine to form a second post and lintel assembly distinct from the first post and lintel assembly.

Abstract: The present invention provides systems and methods employing Voice over Internet Protocol (VoIP) technology to provide multi-channel, multi-access voice communication capabilities.

Abstract: The present invention provides systems and methods employing a conferencing system for facilitating enhanced communication between users. In certain embodiments, the conferencing system comprises a communication interface configured to, during a conference session, provide a virtual and/or augmented conference between multiple users having access to a multi-channel, multi-access, always-on, and non-blocking communication. In particular embodiments, the communication interface is in communication with at least one additional component select from: a video component, a data component (e.g., that provides non-audio data to one or more of said users), an audio/video ambience component, and a whiteboard component.

Abstract: The present invention provides systems and methods employing a conferencing system for facilitating enhanced communication between users. In certain embodiments, the conferencing system comprises a communication interface configured to, during a conference session, provide a virtual and/or augmented conference between multiple users having access to a multi-channel, multi-access, always-on, and non-blocking communication. In particular embodiments, the communication interface is in communication with at least one additional component select from: a video component, a data component (e.g., that provides non-audio data to one or more of said users), an audio/video ambience component, and a whiteboard component.

Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

Abstract: The present invention provides systems and methods employing a conferencing system for facilitating enhanced communication between users. In certain embodiments, the conferencing system comprises a communication interface configured to, during a conference session, provide a virtual and/or augmented conference between multiple users having access to a multi-channel, multi-access, always-on, and non-blocking communication. In particular embodiments, the communication interface is in communication with at least one additional component select from: a video component, a data component (e.g., that provides non-audio data to one or more of said users), an audio/video ambience component, and a whiteboard component.

Abstract: A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

Abstract: The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.

Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

Abstract: The present invention provides systems and methods employing Voice over Internet Protocol (VoIP) technology to provide multi-channel, multi-access voice communication capabilities.

Abstract: The present invention provides systems and methods employing Voice over Internet Protocol (VoIP) technology to provide multi-channel, multi-access voice communication capabilities.

Abstract: The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.

Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

Abstract: The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.